FDA Approval Summary: Olaparib in Combination With Abiraterone for Treatment of Patients With BRCA -Mutated Metastatic Castration-Resistant Prostate Cancer.

Jaleh Fallah Jianjin XuChana WeinstockMichael H BraveErik W BloomquistMallorie H FieroTimothy SchaeferAnand PathakAbdelrahmman AbukhdeirVishal BhatnagarHaw-Jyh ChiuTiffany RicksChristy JohnSalaheldin HamedChristal LeeWilliam F PierceShyam KalavarReena PhilipShenghui Tang Laleh Amiri-Kordestani Richard PazdurPaul G KluetzDaniel Suzman

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)

m, the FDA determined that the modest rPFS improvement, combined with clinically significant toxicities, did not demonstrate a favorable risk/benefit assessment.

Keyphrases

squamous cell carcinoma
small cell lung cancer
combination therapy
drug administration
smoking cessation